ClinicalTrials.Veeva

Find clinical trials for Asthma in New Haven, CT

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Pulmonary Eosinophilia
Allergic Rhinitis
Chronic Obstructive Pulmonary Disease
Obstructive Lung Diseases
Rhinitis
Respiration Disorders
Respiratory Tract Diseases

Asthma trials near New Haven, CT, USA:

A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Eosinophilic Asthma (EXHALE-4)

The purpose of this study is to evaluate dexpramipexole as an add-on oral therapy in participants with inadequately controlled eosinophilic asthma...

Enrolling
Asthma Attack
Asthma; Eosinophilic
Drug: Placebo
Drug: Dexpramipexole Dihydrochloride

Phase 3

Areteia Therapeutics

Hawthorne, New York, United States and 117 other locations

To asses effectiveness and safety of tezepelumab in adult and adolescent participants with severe asthma including several under-studied pop...

Enrolling
Asthma
Drug: Tezepelumab

Phase 4

AstraZeneca
AstraZeneca

New Haven, Connecticut, United States and 44 other locations

and safety of Atuliflapon administered once daily over a 12-week treatment period to adult participants with moderate to severe uncontrolled asthma...

Enrolling
Asthma
Drug: Placebo
Drug: Atuliflapon

Phase 2

AstraZeneca
AstraZeneca

Valhalla, New York, United States and 350 other locations

of clinically significant exacerbations in participants with severe asthma with an eosinophilic phenotype. Throughout the study, all partici...

Enrolling
Asthma
Biological: Placebo
Biological: Mepolizumab

Phase 3

GlaxoSmithKline (GSK)
GlaxoSmithKline (GSK)

New Haven, Connecticut, United States and 429 other locations

variable length study to evaluate the efficacy and safety of budesonide/glycopyrronium/formoterol inhaler in adults and adolescents with severe asthma...

Enrolling
Asthma
Drug: BFF pMDI 320/9 μg
Drug: BGF MDI 320/14.4/9.6 μg

Phase 3

AstraZeneca
AstraZeneca

Port Jefferson, New York, United States and 444 other locations

variable length study to evaluate the efficacy and safety of budesonide/glycopyrronium/formoterol inhaler in adults and adolescents with severe asthma...

Enrolling
Asthma
Drug: BFF pMDI 320/9 μg
Drug: BFF MDI 320/9.6 μg

Phase 3

AstraZeneca
AstraZeneca

Waterbury, Connecticut, United States and 477 other locations

The purpose of the study is to evaluate effect of benralizumab on structural and lung function changes in severe eosinophilic asthmatics.Changes will...

Enrolling
Asthma
Biological: Placebo
Biological: Benralizumab

Phase 4

AstraZeneca
AstraZeneca

Port Jefferson Station, New York, United States and 43 other locations

This study will evaluate the efficacy and safety of depemokimab (GSK3511294) in participants with CRSwNP.

Active, not recruiting
Nasal Polyps
Biological: Depemokimab (GSK3511294)
Drug: Placebo

Phase 3

GlaxoSmithKline (GSK)
GlaxoSmithKline (GSK)

New Haven, Connecticut, United States and 84 other locations

This is a randomized, double-blind, placebo-controlled, parallel-group, international, multicenter, Phase 3 study to evaluate the efficacy and safety...

Active, not recruiting
Nasal Polyposis
Biological: Benralizumab 30 mg
Biological: Matched placebo

Phase 3

AstraZeneca
AstraZeneca

White Plains, New York, United States and 115 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems